RT Journal Article
T1 Predictors of clinically significant quality of life impairment in Parkinson's disease
A1 Garcia, Santos D.
A1 de Deus Fonticoba, Teresa
A1 Cores, Carlos
A1 Munoz, Guillermo
A1 Paz Gonzalez, Jose M.
A1 Martinez Miro, Cristina
A1 Suarez, Ester
A1 Jesus, Silvia
A1 Aguilar, Miquel
A1 Pastor, Pau
A1 Planellas, Lluis
A1 Cosgaya, Marina
A1 Garcia Caldentey, Juan
A1 Caballol, Nuria
A1 Legarda, Ines
A1 Hernandez Vara, Jorge
A1 Cabo, Iria
A1 Lopez Manzanares, Luis
A1 Gonzalez Aramburu, Isabel
A1 Avila Rivera, Maria A.
A1 Catalan, Maria J.
A1 Nogueira, Victor
A1 Puente, Victor
A1 Ruiz de Arcos, Maria
A1 Borrue, Carmen
A1 Solano Vila, Berta
A1 Alvarez Sauco, Maria
A1 Vela, Lydia
A1 Escalante, Sonia
A1 Cubo, Esther
A1 Carrillo Padilla, Francisco
A1 Martinez Castrillo, Juan C.
A1 Sanchez Alonso, Pilar
A1 Alonso Losada, Maria G.
A1 Lopez Ariztegui, Nuria
A1 Gaston, Itziar
A1 Clavero, Pedro
A1 Kulisevsky, Jaime
A1 Blazquez Estrada, Marta
A1 Seijo, Manuel
A1 Ruiz Martinez, Javier
A1 Valero, Caridad
A1 Kurtis, Monica
A1 de Fabregues, Oriol
A1 Gonzalez Ardura, Jessica
A1 Ordas, Carlos
A1 Lopez Diaz, Luis M.
A1 McAfee, Darrian
A1 Martinez-Martin, Pablo
A1 Mir, Pablo
A1 COPPADIS Study Grp, 
K1 Nonmotor symptoms
K1 Gender-differences
K1 Impact
K1 Disability
K1 Questionnaire
K1 Progression
K1 Scale
K1 Determinants
K1 Validation
K1 Onset
AB Quality of life (QOL) plays an important role in independent living in Parkinson's disease (PD) patients, being crucial to know what factors impact QoL throughout the course of the disease. Here we identified predictors of QoL impairment in PD patients from a Spanish cohort. PD patients recruited from 35 centers of Spain from the COPPADIS cohort from January 2016, to November 2017, were followed up during 2 years. Health-related QoL (HRQoL) and global QoL (GQoL) were assessed with the 39-item Parkinson's disease Questionnaire (PDQ-39) and the EUROHIS-QOL 8-item index (EUROHIS-QOL8), respectively, at baseline (V0) and at 24 months +/- 1 month (V2). Clinically significant QoL impairment was defined as presenting an increase (PDQ-39SI) or decrement (EUROHIS-QOL8) at V2 >= 10% of the score at baseline (V0). A comparison with a control group was conducted for GQoL. GQoL did not change significantly in PD patients (N = 507; p = 0.686) or in the control group (N = 119; p = 0.192). The mean PDQ-39SI was significantly increased in PD patients (62.7 +/- 8.5 years old; 58.8% males; N = 500) by 21.6% (from 16.7 +/- 13 to 20.3 +/- 16.4; p = 10% of the score at baseline (V0). A comparison with a control group was conducted for GQoL. GQoL did not change significantly in PD patients (N = 507; p = 0.686) or in the control group (N = 119; p = 0.192). The mean PDQ-39SI was significantly increased in PD patients (62.7 +/- 8.5 years old; 58.8% males; N = 500) by 21.6% (from 16.7 +/- 13 to 20.3 +/- 16.4; p = 5 and >= 10 points of BDI-II and NMSS total score at V2 multiplied the probability of presenting clinically significant HRQoL impairment by 5 (OR = 5.453; 95% CI 1.663-17.876; p = 0.005) and 8 (OR = 8.217; 95% CI, 2.975-22.696; p = 0.002), respectively. In conclusion, age, gender, mood, and non-motor impairment were associated with clinically significant HRQoL impairment after the 2-year follow-up in PD patients.
PB Nature portfolio
YR 2021
FD 2021-12-16
LK https://hdl.handle.net/10668/27942
UL https://hdl.handle.net/10668/27942
LA en
DS RISalud
RD Apr 6, 2025